A novel compound of chiral 4-hydroxy-4-butyrolactam fused aziridine was synthesized via tandem nucleophilic displacement reaction under mild condition. Its structure was determined by IR, 1H NMR, elemental analysis an...A novel compound of chiral 4-hydroxy-4-butyrolactam fused aziridine was synthesized via tandem nucleophilic displacement reaction under mild condition. Its structure was determined by IR, 1H NMR, elemental analysis and X-ray diffraction. The crystal of the new compound is of orthorhombic, space group P212121 with a = 6.4246（6）, b = 13.5081（13）, c = 18.6399（18） A, Mr = 278.39, Z = 4, V = 1617.6（3）A^3, Dc = 1.143 g/cm^3, p（MoKa） = 0.075 mm^-1, F（000） = 608, the final R = 0.0297 and wR = 0.0679.展开更多
Acute coronary syndrome(ACS)is one of the leading causes of death in cardiovascular disease.Percutaneous coronary intervention(PCI)is an important method for the treatment of coronary heart disease(CHD),and it has gre...Acute coronary syndrome(ACS)is one of the leading causes of death in cardiovascular disease.Percutaneous coronary intervention(PCI)is an important method for the treatment of coronary heart disease(CHD),and it has greatly reduced the mortality of ACS patients since its application.However,a series of new problems may occur after PCI,such as in-stent restenosis,no-reflow phenomenon,in-stent neoatherosclerosis,late stent thrombosis,myocardial ischemia-reperfusion injury,and malignant ventricular arrhythmias,which result in the occurrence of major adverse cardiac events(MACE)that seriously reduce the postoperative benefit for patients.The inflammatory response is a key mechanism of MACE after PCI.Therefore,examining effective anti-inflammatory therapies after PCI in patients with ACS is a current research focus to reduce the incidence of MACE.The pharmacological mechanism and clinical efficacy of routine Western medicine treatment for the anti-inflammatory treatment of CHD have been verified.Many Chinese medicine(CM)preparations have been widely used in the treatment of CHD.Basic and clinical studies showed that effectiveness of the combination of CM and Western medicine treatments in reducing incidence of MACE after PCI was better than Western medicine treatment alone.The current paper reviewed the potential mechanism of the inflammatory response and occurrence of MACE after PCI in patients with ACS and the research progress of combined Chinese and Western medicine treatments in reducing incidence of MACE.The results provide a theoretical basis for further research and clinical treatment.展开更多
目的探讨鼻咽癌患者的癌症复发恐惧水平(fear of cancer recurrence,FCR)及影响因素,为制定针对性干预措施提供依据。方法选取2018年3-12月广州市2家三甲医院肿瘤科就诊的228例鼻咽癌患者作为研究对象,采用一般情况调查表、疾病进展恐...目的探讨鼻咽癌患者的癌症复发恐惧水平(fear of cancer recurrence,FCR)及影响因素,为制定针对性干预措施提供依据。方法选取2018年3-12月广州市2家三甲医院肿瘤科就诊的228例鼻咽癌患者作为研究对象,采用一般情况调查表、疾病进展恐惧简化量表(FoP-Q-SF)、领悟社会支持(PSSS)、简易应对方式问卷(SCSQ)进行调查,采用单因素分析、Pearson相关分析、多元逐步回归分析对鼻咽癌患者的FCR进行分析。结果鼻咽癌患者FCR得分为(37.14±9.28)分;单因素分析结果显示,鼻咽癌患者的FCR得分在年龄、受教育程度、月收入、肿瘤临床分期4个变量上存在差异(均P<0.05);Pearson相关分析显示,鼻咽癌患者的FCR与家庭内支持、家庭外支持、领悟社会支持总分、积极应对呈负相关(均P<0.05),与消极应对呈正相关(P<0.05);多元逐步回归分析显示,积极应对、肿瘤临床分期、社会支持、受教育程度依次进入回归方程(F=29.842,P<0.001;R^2=0.368,调整R^2=0.356)。结论鼻咽癌患者的FCR水平较高,积极应对、肿瘤临床分期、社会支持、受教育程度是鼻咽癌患者的FCR的主要影响因素。医护人员应关注鼻咽癌患者的FCR水平,制定针对性的干预措施,帮助患者建立和维持良好的社会支持系统,鼓励患者积极应对,从而降低和控制患者的FCR水平。展开更多
基金Project supported by key subject of Luoyang Normal University (No. 2004yzk90)
文摘A novel compound of chiral 4-hydroxy-4-butyrolactam fused aziridine was synthesized via tandem nucleophilic displacement reaction under mild condition. Its structure was determined by IR, 1H NMR, elemental analysis and X-ray diffraction. The crystal of the new compound is of orthorhombic, space group P212121 with a = 6.4246（6）, b = 13.5081（13）, c = 18.6399（18） A, Mr = 278.39, Z = 4, V = 1617.6（3）A^3, Dc = 1.143 g/cm^3, p（MoKa） = 0.075 mm^-1, F（000） = 608, the final R = 0.0297 and wR = 0.0679.
基金Supported by the Applied Technology Research and Development and Demonstration Projects of Beijing Province(No.Z191100006619071)。
文摘Acute coronary syndrome(ACS)is one of the leading causes of death in cardiovascular disease.Percutaneous coronary intervention(PCI)is an important method for the treatment of coronary heart disease(CHD),and it has greatly reduced the mortality of ACS patients since its application.However,a series of new problems may occur after PCI,such as in-stent restenosis,no-reflow phenomenon,in-stent neoatherosclerosis,late stent thrombosis,myocardial ischemia-reperfusion injury,and malignant ventricular arrhythmias,which result in the occurrence of major adverse cardiac events(MACE)that seriously reduce the postoperative benefit for patients.The inflammatory response is a key mechanism of MACE after PCI.Therefore,examining effective anti-inflammatory therapies after PCI in patients with ACS is a current research focus to reduce the incidence of MACE.The pharmacological mechanism and clinical efficacy of routine Western medicine treatment for the anti-inflammatory treatment of CHD have been verified.Many Chinese medicine(CM)preparations have been widely used in the treatment of CHD.Basic and clinical studies showed that effectiveness of the combination of CM and Western medicine treatments in reducing incidence of MACE after PCI was better than Western medicine treatment alone.The current paper reviewed the potential mechanism of the inflammatory response and occurrence of MACE after PCI in patients with ACS and the research progress of combined Chinese and Western medicine treatments in reducing incidence of MACE.The results provide a theoretical basis for further research and clinical treatment.
文摘目的探讨鼻咽癌患者的癌症复发恐惧水平(fear of cancer recurrence,FCR)及影响因素,为制定针对性干预措施提供依据。方法选取2018年3-12月广州市2家三甲医院肿瘤科就诊的228例鼻咽癌患者作为研究对象,采用一般情况调查表、疾病进展恐惧简化量表(FoP-Q-SF)、领悟社会支持(PSSS)、简易应对方式问卷(SCSQ)进行调查,采用单因素分析、Pearson相关分析、多元逐步回归分析对鼻咽癌患者的FCR进行分析。结果鼻咽癌患者FCR得分为(37.14±9.28)分;单因素分析结果显示,鼻咽癌患者的FCR得分在年龄、受教育程度、月收入、肿瘤临床分期4个变量上存在差异(均P<0.05);Pearson相关分析显示,鼻咽癌患者的FCR与家庭内支持、家庭外支持、领悟社会支持总分、积极应对呈负相关(均P<0.05),与消极应对呈正相关(P<0.05);多元逐步回归分析显示,积极应对、肿瘤临床分期、社会支持、受教育程度依次进入回归方程(F=29.842,P<0.001;R^2=0.368,调整R^2=0.356)。结论鼻咽癌患者的FCR水平较高,积极应对、肿瘤临床分期、社会支持、受教育程度是鼻咽癌患者的FCR的主要影响因素。医护人员应关注鼻咽癌患者的FCR水平,制定针对性的干预措施,帮助患者建立和维持良好的社会支持系统,鼓励患者积极应对,从而降低和控制患者的FCR水平。
